Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine
BALTIMORE, Oct. 8, 2021 — Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced it has entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) for the rights to commercialize its self-replicating RNA vaccine for COVID-19, called EXG-5003, […]
Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine Read More »